The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas

Iranian Journal of Allergy, Asthma and Immunology

Volumn 4, Issue 2, 2005, Pages 83-90

  Panahi, Yunes ^a   Ghanei, Mostafa ^a   Aslani, Jafar ^a   Mojtahedzadeh, Mojtaba ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bronchiolitis Obliterans; Interferon Gamma 1b; Mustard Gas

Indexed keywords

BECLOMETASONE; GAMMA1B INTERFERON; MUSTARD GAS; PREDNISOLONE; SALBUTAMOL;

ADULT; ARTERIAL GAS; ARTICLE; BRONCHIOLITIS; CHEMICAL INJURY; CHRONIC DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LESION; MALE; PNEUMOTACHYGRAPHY; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84966569787     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Reports of specialists appointed by the Secretary General to investigate allegations by the Islamic Republic of Iran concerning the use of chemical weapons. New York Security Council of United Nations document, 1986; 16433.
2. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45(11):1136-43.
3. Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997; 112(3):734-8.
4. Thomason JW, Rice TW, Milstone AP. Bronchiolitis obliterans in a survivor of a chemical weapons attack. JAMA 2003; 290(5):598-9.
5. El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, et al. Transforming growth factor beta (TGFbeta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18(9):828-37.
6. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100(4):768-76.
7. Du Bois RM. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 1999; 341(17):1302-4.
8. Hassan ZM, Ebtekar M. Immunological consequence of sulfur mustard exposure. Immunol Lett 2002; 83(3):151-2.
9. Kahari VM, Chen YQ, Su MW, Ramirez F, Uitto J. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mecha-nisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest 1990; 86(5):1489-95.
10. Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest 1990; 20(5):487-93.
11. Yufit T, Vining V, Wang L, Brown RR, Varga J. Inhibition of type I collagen mRNA expression independent of tryptophan depletion in interferongamma- treated human dermal fibroblasts. J Invest Dermatol 1995; 105(3):388-93.
12. Higashi K, Kouba DJ, Song YJ, Uitto J, Mauviel A. A proximal element within the human alpha 2(I) collagen (COL1A2) promoter, distinct from the tumor necrosis factor-alpha response element, mediates transcriptional repression by interferon-gamma. Matrix Biol 1998; 16(8):447-56.
13. Yuan W, Yufit T, Li L, Mori Y, Chen SJ, Varga J. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma. J Cell Physiol 1999; 179(1):97-108.
14. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133(1):97-103.
15. American Thoracic Society Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136(5):1285-98.
16. Moses HL, Pietenpol JA, Munger K, Murphy CS, Yang EY. TGF beta regulation of epithelial cell proliferation: role of tumor suppressor genes. Princess Takamatsu Symp 1991; 22:183-95.
17. Sosroseno W, Herminajeng E. The immuno-regulatory roles of transforming growth factor beta. Br J Biomed Sci 1995; 52(2):142-8.
18. Sporn MB, Roberts AB. TGF-beta: problems and prospects. Cell Regul 1990; 1(12):875-82.
19. Denis M. Neutralization of transforming growth factorbeta 1 in a mouse model of immune-induced lung fibrosis Immunology 1994; 82(4):584-90.
20. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycinmouse model of lung fibrosis: downregulation of TGFbeta and procollagen I and III gene expression. Exp Lung Res 1995; 21(5):791-808.
21. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growthfactor beta on bleomyein induced accumulation of lung collagen in mice Thorax 1993; 48(10):959-66.
22. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96(5):2345-9.
23. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2(4):418-23.
24. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104(1):5-11.
25. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324(14):933-40.
26. Noble NA. Border WA. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17(5):455-66.
27. Bayer EM, Herr W, Kanzler S, Waldmann C, Meyer Zum Buschenfelde KH, et al. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998; 28(5):803-11.
28. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. Reduced plasma transforming growth factorbeta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol 1999; 30(1);1-7
29. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999 21; 341(17):1264-9
30. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol 1999; 30(1):1-7.
31. Ziesche R, Kink E. Therapy of chronic interstitial lung disease with a combination of interferon gamma-1b and low dose prednisolone. Chest 1996; 110(21):110-115.